The Sage Group Expands its Global Reach to Australia and Israel with New Executive Directors
Date: 18 Dec 2009
Cambridge UK and Clinton USA – December 2009 – The Sage Group is pleased to announce the appointment of two new seasoned Executive Directors – Dr. Tom Geimer in Australia and Dr. Laurence Shaw in Israel. Drs. Geimer and Shaw bring a breadth of additional experience and contacts in the healthcare and life science industry and financial sectors to Sage.
“We are very pleased that Laurence and Tom have joined Sage as Executive Directors. They will significantly expand our capability and expertise in serving the strategic transactional needs of our clients in the key territories of Israel and Australasia” said Wayne Pambianchi, Managing Director of Sage. “Their strong healthcare and life science industry backgrounds will bring a strong new dimension to the services we provide our clients, and will assist in the value creation process that Sage brings to all of our clients.”
Dr. Tom Geimer has an honors degree in molecular biology and a PhD in veterinary science from University of Wisconsin at Madison. He also holds a certification in veterinary anesthesiology from the Cornell University and an MBA from London Business School, where he was an international Rotary Scholar. Dr. Geimer has held positions in various start-ups, corporate management in Germany and on the stock market in the city of London. As a top rated Excel analyst Tom was christened into life sciences in the early days in Europe. Moving from corporate finance into private equity, he has a vast network of contemporary relationships throughout the brokerage and banking sectors. Tom joined Heidelberg Innovations (HI) in 2005 after five years as a Senior Partner with Apax Partners Private Equity and as a private Advisor to HI. Tom was involved with several of the larger transactions at Apax including three corporate spin-outs. In addition, his extensive network resulted in his securing several proprietary deals for Apax including Wilex and Atugen. Tom acted as the primary team member on Genmab which returned over 500% IRR and is one of, if not, the top ranking healthcare transaction in the 25 year history of Apax. In 2008, Tom emigrated to Australia where he runs his corporate finance practice. He maintains strong US and European links. He joined The Sage Group in 2009.
Dr. Laurence Shaw, M.D. is the founder of Human Life Sciences, an international life science consulting practice that focuses on improving the productivity and profitability of Life Science companies. Dr. Shaw served as Corporate Vice President of Research and Development at C.R. Bard, Inc. At Abbott Laboratories, he was Vice President of Medical and Regulatory Affairs and Advanced Research. Previously, he was a board member of Revlon Health Care, Ltd. (UK) and Director of Medical and Technical Affairs. Dr. Shaw founded Atlantic Pharmaceuticals (now called Manhattan Pharmaceuticals), a public company, and was its CEO and President. Dr. Shaw was Chief Executive Officer and a director of Applied Spectral Imaging Ltd. Dr. Shaw also served as CEO and President of Pacific Pharmaceuticals, Inc. as well as Chairman of its board. Currently, Dr. Shaw is the Chairman of ConjuGate Ltd, and Biokine Therapeutics Ltd, acts as executive advisor to the Life Science Industry and sits on the board of several startup companies.
About The Sage Group, Inc.
The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel, Australia and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million. The establishment of operations in Europe and Japan over recent years allows its clients to reach out beyond their own regions and capture the potential of the global healthcare market.
The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.
The range of services offered includes:
• Strategic alliances and licensing/partnering
• M&A, divestment, buy- and sell- side
• Global product and technology acquisition searches
• Strategic assessment and planning
• Due diligence, technology and molecule assessment, valuation
• New ventures, interim management
• Facilitating investment in R&D and/or company equity through introductions, network and brokering
The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals have also held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist industry participants in these challenging times.
The Sage Group can be contacted at any of the offices shown below:
The Sage Group Inc.
1802 Route 31 North, #381
Clinton, NJ 08809
Attn: Wayne Pambianchi
Tel: +1 908-231-9644
Fax: +1 908-231-9692
Sage Healthcare Ltd.
Church Street Barns
Cambridge CB22 5EL UK
Attn: Dr. Bill Mason
Tel: +44 (0) 1223 844128
Fax: +44 (0) 1223 847871
Sage Japan Inc.
Attn: Yoshi Mizuta
8/4 Heh BéIyar St.
Attn: Laurence Shaw
Tel: +972 508927789
PO Box 1474, Lot 24
Williams Road, Summit Fire Track Mount Barker
South Australia 5251
Attn: Tom Geimer
Tel: +61 4160 599 75